0000000000136107

AUTHOR

Pablo Catalán

0000-0003-2826-4684

showing 8 related works from this author

Parsimonious scenario for the emergence of viroid-like repliconsde novo

2019

AbstractViroids are small, non-coding, circular RNA molecules that infect plants. Different hypotheses for their evolutionary origin have been put forward, such as an early emergence in a precellular RNA World or severalde novoindependent evolutionary origins in plants. Here we discuss the plausibility ofde novoemergence of viroid-like replicons by giving theoretical support to the likelihood of different steps along a parsimonious evolutionary pathway. While Avsunviroidae-like structures are relatively easy to obtain through evolution of a population of random RNA sequences of fixed length, rod-like structures typical of Pospiviroidae are difficult to fix. Using different quantitative appr…

education.field_of_studybiologyViroidvirusesPospiviroidaePopulationRNAComputational biologybiology.organism_classificationCircular RNAbiology.proteinRepliconSequence motifeducationPolymerase
researchProduct

Parsimonious Scenario for the Emergence of Viroid-Like Replicons De Novo

2019

This article belongs to the Special Issue Viroid-2018: International Conference on Viroids and Viroid-Like RNAs. Viroids are small, non-coding, circular RNA molecules that infect plants. Different hypotheses for their evolutionary origin have been put forward, such as an early emergence in a precellular RNA World or several de novo independent evolutionary origins in plants. Here, we discuss the plausibility of de novo emergence of viroid-like replicons by giving theoretical support to the likelihood of different steps along a parsimonious evolutionary pathway. While Avsunviroidae-like structures are relatively easy to obtain through evolution of a population of random RNA sequences of fixe…

0301 basic medicinePopulation dynamicsViroidMatemáticasvirusesPopulationPospiviroidaelcsh:QR1-502Computational biologycomputational simulationsVirus Replicationlcsh:MicrobiologyArticleNucleic acid secondary structureEvolution MolecularViral Proteins03 medical and health sciences0302 clinical medicineCircular RNAVirologypopulation dynamicsModular evolutionRepliconeducationPolymeraseBiología y BiomedicinaSimple replicatorsComputational simulationseducation.field_of_studyViroidstructure enumerationbiologysimple replicatorsviroidStructure enumerationRNARNA Circularbiology.organism_classificationRNA secondary structureViroids030104 developmental biologyInfectious Diseasesbiology.proteinNucleic Acid ConformationRNA ViralRepliconmodular evolution030217 neurology & neurosurgeryViruses
researchProduct

Differences between Community Acquired Legionnaire's Pneumonia (CAP-L) and Pneumococcal Pneumonia (CAP-P).

2009

medicine.medical_specialtyPneumoniabusiness.industryInternal medicinePneumococcal pneumoniamedicinemedicine.diseasebusinessA47. COMMUNITY ACQUIRED PNEUMONIA AND HEALTHCARE ASSOCIATED PNEUMONIA
researchProduct

Spanish Version Of The Sleep Apnoea Quality Of Life Index (SAQLI)

2010

Gerontologybusiness.industryMedicineSpanish versionbusinessSleep in non-human animalsC68. OBSTRUCTIVE SLEEP APNEA DIAGNOSIS AND DIAGNOSTIC TOOLS
researchProduct

Is It Important To Correlate HRCT Visual Score With Pulmonary Function Tests (PFT) In IPF Patients?

2010

medicine.medical_specialtyVisual scorebusiness.industryInternal medicinemedicineCardiologybusinessPulmonary function testingA103. INSIGHTS INTO IMAGING, DIAGNOSIS AND TREATMENT OF INTERSTITIAL LUNG DISEASE
researchProduct

Spanish Version Of The Quebec Sleep Questionnaire (QSQ)

2010

Spanish versionPsychologySleep in non-human animalsClinical psychologyC68. OBSTRUCTIVE SLEEP APNEA DIAGNOSIS AND DIAGNOSTIC TOOLS
researchProduct

Effect Of 8-week 320 Mg Megestrol acetate Daily Administration In Severe COPD And Weight Loss

2010

medicine.medical_specialtyEndocrinologyWeight lossbusiness.industryInternal medicineMegestrol acetatemedicinemedicine.symptomSevere copdbusinessGastroenterologymedicine.drugC42. CHRONIC OBSTRUCTIVE PULMONARY DISEASE PHARMACOLOGIC INTERVENTIONS AND OUTCOMES
researchProduct

WHY LOW RISK COMMUNITTY ACQUIRED PNEUMONIA (PSI I-III) ARE ADMITTED TO ICU?

2010

Pneumoniamedicine.medical_specialtybusiness.industryEmergency medicineMedicineMedical emergencybusinessmedicine.diseaseB50. RESPIRATORY TRACT INFECTIONS: DIAGNOSIS AND PROGNOSIS
researchProduct